TRDA Stock Analysis: Buy, Sell, or Hold?
TRDA - Entrada Therapeutics, Inc. Common Stock
$7.16
0.37 (5.45%)
▲
5d:
+17.76%
30d:
-7.25%
90d:
-50.62%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
1d
Get Alerted When TRDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: TRDA shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: TRDA shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: TRDA is currently trading at $7.16, which is considered fair relative to its 30-day fair value range of $6.32 to $7.47.
Technical Outlook: Technically, TRDA is in a strong downtrend. The price is approaching resistance at $7.25. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: TRDA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $18.75 (+176.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TRDA is in a strong downtrend. The price is approaching resistance at $7.25. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: TRDA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $18.75 (+176.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$6.32 -
$7.47
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
92.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.4%)
- BULLISH: Trading 176.1% below Wall St target ($18.75)
Trading Range Analysis
30-Day Trading Range
$6.32 -
$7.47
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$5.72
Resistance Level
$7.26
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.08
Wall Street Target
$18.75
(+176.1%)
Revenue Growth (YoY)
-95.7%
Share & Embed Analysis
Last updated: August 03, 2026 2:23 PM ET
Data refreshes hourly during market hours. Next update: 3:23 PM
Data refreshes hourly during market hours. Next update: 3:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TRDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Kory James Wentworth
SELL
2500 shares
2026-04-01
Kory James Wentworth
SELL
11388 shares
2026-03-10
Nathan J Dowden
SELL
11894 shares
2026-03-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 47 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 47 HOLD |